Chemed Corporation — Third Quarter 2026 Earnings Summary

Chemed Corporation reported third-quarter 2026 consolidated revenue of $690.9 million, representing a 10.6% increase from the prior year, with GAAP diluted earnings per share rising 22.2% to $5.45. The VITAS segment drove growth with a 12.2% increase in net patient revenue to $457.4 million and a 31.4% rise in adjusted EBITDA excluding the Medicare Cap, while Roto-Rooter segment revenue grew 7.5% to $233.5 million despite a slight decline in adjusted EBITDA. During the quarter, the company repurchased 125,000 shares for $66.0 million and re-acquired multiple franchise territories in California for approximately $62.5 million. Chemed updated its full-year 2026 adjusted EPS guidance to be at or slightly above the high-end of its previous range.